Scholarlink

<p>This study aimed to investigate the cardioprotective role and underlying mechanisms of the endogenous metabolite mesaconate in both acute and chronic cardiovascular disease models, with a focus on its regulation of macrophage inflammation. Transcriptomic profiling and functional validation in bone marrow-derived macrophages suggested GPR35 as a potential target of mesaconate. Further mechanistic studies revealed that mesaconate alleviates macrophage ferroptosis via GPR35, thereby contributing to its anti-inflammatory effects. In a myocardial ischemia/reperfusion model, mesaconate significantly attenuated cardiac injury, improved systolic function, and reduced infarct size, while myeloid-specific GPR35 knockdown abolished these protective effects. In aged mice, mesaconate ameliorated cardiac hypertrophy and vascular dysfunction, effects closely associated with suppressed macrophage inflammation. Collectively, this study demonstrates for the first time that mesaconate alleviates macrophage inflammation by activating GPR35 to suppress ferroptosis, confers GPR35-dependent cardioprotection in ischemic injury, and mitigates aging-related cardiovascular pathology, highlighting mesaconate as a promising therapeutic candidate for inflammatory cardiovascular diseases.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mesaconate Alleviates Myocardial Ischemia/Reperfusion Injury and Cardiovascular Aging by Targeting GPR35 to Arrest Macrophage Inflammation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月25日

查看全文
  • Lei Zhu,
  • Jun Cui,
  • Panpan Li,
  • Wenju Shan,
  • Qiang Wang,
  • Wenli Lei,
  • Haitao Zhou,
  • Yang Sun,
  • Wei Yi

摘要

This study aimed to investigate the cardioprotective role and underlying mechanisms of the endogenous metabolite mesaconate in both acute and chronic cardiovascular disease models, with a focus on its regulation of macrophage inflammation. Transcriptomic profiling and functional validation in bone marrow-derived macrophages suggested GPR35 as a potential target of mesaconate. Further mechanistic studies revealed that mesaconate alleviates macrophage ferroptosis via GPR35, thereby contributing to its anti-inflammatory effects. In a myocardial ischemia/reperfusion model, mesaconate significantly attenuated cardiac injury, improved systolic function, and reduced infarct size, while myeloid-specific GPR35 knockdown abolished these protective effects. In aged mice, mesaconate ameliorated cardiac hypertrophy and vascular dysfunction, effects closely associated with suppressed macrophage inflammation. Collectively, this study demonstrates for the first time that mesaconate alleviates macrophage inflammation by activating GPR35 to suppress ferroptosis, confers GPR35-dependent cardioprotection in ischemic injury, and mitigates aging-related cardiovascular pathology, highlighting mesaconate as a promising therapeutic candidate for inflammatory cardiovascular diseases.